Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
作者信息
Ohashi Hirofumi, Koizumi Yoshiki, Fukano Kento, Wakita Takaji, Perelson Alan S, Iwami Shingo, Watashi Koichi
机构信息
Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Department of Applied Biological Sciences, Tokyo University of Science, Noda 278-8510, Japan.
出版信息
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16.
Abstract
摘要
相似文献
1
Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.对帕德马纳班和迪克西特的回复：丙型肝炎病毒进入抑制剂，用于优化基于直接作用抗病毒药物的治疗。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16.
2
Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.社论：丙型肝炎直接抗病毒药物与肾脏——作者回复
Aliment Pharmacol Ther. 2017 Aug;46(3):379-380. doi: 10.1111/apt.14187.
3
Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".回复：“丙型肝炎合并Child's C级肝硬化患者接受直接抗病毒治疗期间的高死亡率：爱尔兰早期获取计划的结果”
J Hepatol. 2016 Aug;65(2):448. doi: 10.1016/j.jhep.2016.04.011. Epub 2016 Apr 27.
4
Direct-acting antiviral therapy for hepatitis E virus?戊型肝炎病毒的直接抗病毒治疗？
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):154-155. doi: 10.1016/S2468-1253(16)30242-4. Epub 2017 Feb 9.
5
New Direct-Acting Antiviral Agents Can Be Hepatotoxic in Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis.新型直接抗病毒药物可能对丙型肝炎病毒感染且失代偿期肝硬化患者具有肝毒性。
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1669-1671. doi: 10.1016/j.cgh.2016.06.009. Epub 2016 Jun 18.
6
Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.慢性丙型肝炎感染接受直接抗病毒药物治疗后出现的乙型肝炎病毒再激活
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):145-147. doi: 10.1016/S2468-1253(18)30004-9. Epub 2018 Jan 19.
7
Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments.在广泛可获得直接抗病毒治疗的监狱中丙型肝炎再感染情况。
Int J Drug Policy. 2020 Mar;77:102597. doi: 10.1016/j.drugpo.2019.11.005. Epub 2020 Jan 15.
8
Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy.直接抗病毒治疗后病毒清除后持续存在的丙型肝炎病毒相关冷球蛋白血症性血管炎。
Hepatology. 2017 May;65(5):1770-1771. doi: 10.1002/hep.28981. Epub 2017 Feb 9.
9
Direct-acting antiviral treatment for hepatitis C.丙型肝炎的直接抗病毒治疗
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
10
Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance.对丙型肝炎直接抗病毒药物的担忧——令人安心的理由
JAMA Netw Open. 2019 Jun 5;2(6):e194757. doi: 10.1001/jamanetworkopen.2019.4757.
引用本文的文献
1
Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.突变途径图谱和起源效应定义了宿主内丙型肝炎病毒耐药突变体的范围。
PLoS Pathog. 2019 Apr 1;15(4):e1007701. doi: 10.1371/journal.ppat.1007701. eCollection 2019 Apr.
2
Building a mechanistic mathematical model of hepatitis C virus entry.建立丙型肝炎病毒进入的机制数学模型。
PLoS Comput Biol. 2019 Mar 18;15(3):e1006905. doi: 10.1371/journal.pcbi.1006905. eCollection 2019 Mar.
3
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.在丙型肝炎病毒感染中，干扰素在细胞、个体和群体水平上的作用：在无干扰素治疗时代的作用。
Immunol Rev. 2018 Sep;285(1):55-71. doi: 10.1111/imr.12689.
4
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.建立模型，研究对干扰素的反应性如何改善丙型肝炎病毒感染的无干扰素治疗。
PLoS Comput Biol. 2018 Jul 12;14(7):e1006335. doi: 10.1371/journal.pcbi.1006335. eCollection 2018 Jul.
本文引用的文献
1
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.丙型肝炎病毒进入抑制剂可能是最佳药物组合的有效成分。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4524-E4526. doi: 10.1073/pnas.1704531114. Epub 2017 May 16.
2
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.量化抗病毒活性可优化针对丙型肝炎病毒感染的药物组合。
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927. doi: 10.1073/pnas.1610197114. Epub 2017 Feb 7.
3
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.使用靶向紧密连接蛋白-1的单克隆抗体清除人源化小鼠体内的持续性丙型肝炎病毒感染
Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.
4
Broadly neutralizing antibodies abrogate established hepatitis C virus infection.广泛中和抗体可消除已有的丙型肝炎病毒感染。
Sci Transl Med. 2014 Sep 17;6(254):254ra129. doi: 10.1126/scitranslmed.3009512.
5
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.进入抑制剂与直接作用抗病毒药物的协同作用揭示了预防和治疗丙型肝炎的新组合。
Gut. 2015 Mar;64(3):483-94. doi: 10.1136/gutjnl-2013-306155. Epub 2014 May 21.
6
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.人源单克隆抗体HCV1可有效预防和治疗黑猩猩的丙型肝炎病毒感染。
PLoS Pathog. 2012;8(8):e1002895. doi: 10.1371/journal.ppat.1002895. Epub 2012 Aug 30.
7
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.EGFR 和 EphA2 是丙型肝炎病毒进入宿主的因素，也是抗病毒治疗的潜在靶点。
Nat Med. 2011 May;17(5):589-95. doi: 10.1038/nm.2341. Epub 2011 Apr 24.
8
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.剂量反应曲线斜率为抗HIV药物的抑制潜力设定了特定类别的限制。
Nat Med. 2008 Jul;14(7):762-6. doi: 10.1038/nm1777. Epub 2008 Jun 15.
9
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.广泛中和抗体可抵御丙型肝炎病毒准种攻击。
Nat Med. 2008 Jan;14(1):25-7. doi: 10.1038/nm1698. Epub 2007 Dec 6.
10
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.药物联合研究中协同作用和拮抗作用的理论基础、实验设计及计算机模拟
Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10.
Zotero 插件